A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2006; you can also visit the original URL.
The file type is
Lecture Notes in Computer Science
Y. ... • Coping with federations and farms of databases • Coping with a variety of different data types • Internet integrity and policies establishment and enforcement • Law and Internet law Co-author Leah ...doi:10.1007/3-540-48854-5_23 fatcat:pw2yclmmczeyhmjlsljmjlxcgm
Background With the advent of innovative therapies including biologics and Janus kinase inhibitors, children with rheumatic diseases are more likely to have improved outcomes. Despite these advances, some children do not respond, or they, or their parents fear adverse events and seek other alternatives. Increasingly, private companies are offering mesenchymal stem cells (MSC) as an alternative, which are described as natural therapies for rheumatic diseases, often insinuating them as a cure.doi:10.1186/s12969-021-00575-5 pmid:34112214 pmcid:PMC8194100 fatcat:vmiptcwpmjh3vgy656x5pjkicy
more »... have immunomodulatory properties, and transplantation of these stem cells have been used to successfully treat immunologic conditions like graft-versus-host disease. Lately, MSC research in adult lupus has been encouraging, but the clinical trials are still underway and in most, MSC therapy is not a standalone treatment. This retrospective case series will highlight three cases of pediatric refractory autoimmune disease whose parents sought out and received MSC therapy as a self-decision without first seeking medical advice from our specialty. The three families felt that their children were improved and in two believed that their child was cured. MSC have the potential of beneficial immunomodulation and may be a powerful tool in the therapy of rheumatic disease, but well controlled clinical trials are necessary and should be designed and monitored by experts in childhood rheumatic disease. Case presentation Three children with three different rheumatic diseases; systemic lupus erythematosus, mixed connective tissue disease and juvenile idiopathic arthritis were under the care of pediatric rheumatology at a large, tertiary-care, teaching institution. Multiple non-biologic and biologic disease-modifying anti-rheumatic drugs failed to significantly decrease disease activity, and as a result, the families chose to undergo MSC therapy. After transplantation, all children improved per patient and parent report and tapered off conventional immunosuppressive drugs. No serious adverse events occurred in these three patients. Conclusion The three cases presented in this report reflect comparable beneficial outcomes and minimal risks published in adult studies. These were not controlled studies, however, and benefit was reported rather than documented. These cases suggest that MSC transplantation may prove a promising adjunctive treatment option; however, further research, development of standardized infusion therapy protocols, and well-designed monitored clinical trials are essential.
During CDC's response to the 2014-2016 Ebola virus disease (Ebola) epidemic in West Africa, U.S. and international public health decision-makers and stakeholders needed information early in the epidemic. This information included the number of Ebola cases that could be expected over time; the resources and personnel needed to respond adequately; and the impact of interventions, such as Ebola treatment units Summary To aid decision-making during CDC's response to the 2014-2016 Ebola virusdoi:10.15585/mmwr.su6503a12 pmid:27387097 fatcat:wpmsmmq5qncltfgxltrk4c4gou
more »... (Ebola) epidemic in West Africa, CDC activated a Modeling Task Force to generate estimates on various topics related to the response in West Africa and the risk for importation of cases into the United States. Analysis of eight Ebola response modeling projects conducted during August 2014-July 2015 provided insight into the types of questions addressed by modeling, the impact of the estimates generated, and the difficulties encountered during the modeling. This time frame was selected to cover the three phases of the West African epidemic curve. Questions posed to the Modeling Task Force changed as the epidemic progressed. Initially, the task force was asked to estimate the number of cases that might occur if no interventions were implemented compared with cases that might occur if interventions were implemented; however, at the peak of the epidemic, the focus shifted to estimating resource needs for Ebola treatment units. Then, as the epidemic decelerated, requests for modeling changed to generating estimates of the potential number of sexually transmitted Ebola cases. Modeling to provide information for decision-making during the CDC Ebola response involved limited data, a short turnaround time, and difficulty communicating the modeling process, including assumptions and interpretation of results. Despite these challenges, modeling yielded estimates and projections that public health officials used to make key decisions regarding response strategy and resources required. The impact of modeling during the Ebola response demonstrates the usefulness of modeling in future responses, particularly in the early stages and when data are scarce. Future modeling can be enhanced by planning ahead for data needs and data sharing, and by open communication among modelers, scientists, and others to ensure that modeling and its limitations are more clearly understood. The activities summarized in this report would not have been possible without collaboration with many U.S. and international partners
OBJECTIVES This study sought to determine if diffuse ventricular fibrosis improves in patients with atrial fibrillation (AF)-mediated cardiomyopathy following the restoration of sinus rhythm. BACKGROUND AF coexists in 30% of heart failure (HF) patients and may be an underrecognized reversible cause of left ventricular systolic dysfunction. Myocardial fibrosis is the hallmark of adverse cardiac remodeling in HF, yet its reversibility is unclear. METHODS Patients with persistent AF and andoi:10.1016/j.jacep.2018.04.013 pmid:30139501 fatcat:w34yg76jdjhuxikx7vop4odmvq
more »... ic cardiomyopathy (left ventricular ejection fraction [LVEF] #45%) were randomized to catheter ablation (CA) or ongoing medical rate control as a pre-specified substudy of the CAMERA-MRI (Catheter Ablation versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction-an MRI-Guided Multi-centre Randomised Controlled Trial) trial. All patients had cardiac magnetic resonance imaging scans (including myocardial T1 time), serum B-type natriuretic peptide, 6-min walk tests, and Short Form-36 questionnaires performed at baseline and 6 months. Sixteen patients with no history of AF or left ventricular systolic dysfunction were enrolled as normal controls for T1 time. RESULTS Thirty-six patients (18 in each treatment arm) were included in this substudy. Demographics, comorbidities, and myocardial T1 times were well matched at baseline. At 6 months, patients in the CA group had a significant reduction in myocardial T1 time from baseline compared with the medical rate control group (À124 ms; 95% confidence interval [CI]: À23 to À225 ms; p ¼ 0.0176), although it remained higher than that of normal controls at 6 months (p ¼ 0.0017). Improvements in myocardial T1 time with CA were associated with significant improvements in absolute LVEF (þ12.5%; 95% CI: 5.9% to 19.0%; p ¼ 0.0004), left ventricular end-systolic volume (p ¼ 0.0019), and serum B-type natriuretic peptide (À216 ng/l; 95% CI: À23 to À225 ng/l; p ¼ 0.0125). CONCLUSIONS The improvement in LVEF and reverse ventricular remodeling following successful CA of AF-mediated cardiomyopathy is accompanied by a regression of diffuse fibrosis. This suggests timely treatment of arrhythmia-mediated cardiomyopathy may minimize irreversible ventricular remodeling. (J Am Coll Cardiol EP 2018;-:---)
., 1385 Varouhakis, Miron, 1604 Vick, Sarah-Jane, 1696 Vincent, Diane, 1432 Vinograd, Jessica, 1419 Vliegenthart, Rens, 1453 Volcic, Zala, 1437 Waks, Leah, 1637 Waller, Bridget M., 1696 Walther, Joseph ... Kingsley, 1674 White, Charles D., 1466 Wilkins, Lee, 1605 Williams, Peyton, 1424 Wilson, Greg, 1475, 1657 Wojcieszak, Magdalena E.., 1578 Wong-Kim, Evaon, 1431 Author Index 763 Woodstock, Louise, 1698 ...
Sage Urban Studies Abstracts
, Man Sing, 0209 Wong, S. ... S., 0124 Tsoodle, Leah J., 0120 Turnbull, Geoffrey K., 0121 Turner, Chris, 0188 Tzfadia, Erez, 0122 Vaiou, Dina, 0190 Vale, Brenda, 0231 Vale, Robert, 0231 van Beckhoven, Ellen, 0191 van Blerk, Lorraine ...
The Journal of Neuroscience
Wong W, Scott JD (2004) AKAP signaling complexes: focal points in space and time. Nat Rev Mol Cell Biol 5:959-970. ... Tang HL, LeAH, Lung HL (2006) The increase in mitochondrial association with actin precedes Bax translocation in apoptosis. Biochem J 396:1-—5. ...
MAPT mutations typically cause behavioral variant frontotemporal dementia with or without parkinsonism. Previous studies have shown that symptomatic MAPT mutation carriers have frontotemporal atrophy, yet studies have shown mixed results as to whether presymptomatic carriers have low gray matter volumes. To elucidate whether presymptomatic carriers have lower structural brain volumes within regions atrophied during the symptomatic phase, we studied a large cohort of MAPT mutation carriers usingdoi:10.1002/acn3.51249 pmid:33247623 pmcid:PMC7818091 fatcat:eo5bxsnhifbllipwdkdnitnzmq
more »... a voxelwise approach. We studied 22 symptomatic carriers (age 54.7 ± 9.1, 13 female) and 43 presymptomatic carriers (age 39.2 ± 10.4, 21 female). Symptomatic carriers' clinical syndromes included: behavioral variant frontotemporal dementia (18), an amnestic dementia syndrome (2), Parkinson's disease (1), and mild cognitive impairment (1). We performed voxel-based morphometry on T1 images and assessed brain volumetrics by clinical subgroup, age, and mutation subtype. Symptomatic carriers showed gray matter atrophy in bilateral frontotemporal cortex, insula, and striatum, and white matter atrophy in bilateral corpus callosum and uncinate fasciculus. Approximately 20% of presymptomatic carriers had low gray matter volumes in bilateral hippocampus, amygdala, and lateral temporal cortex. Within these regions, low gray matter volumes emerged in a subset of presymptomatic carriers as early as their thirties. Low white matter volumes arose infrequently among presymptomatic carriers. A subset of presymptomatic MAPT mutation carriers showed low volumes in mesial temporal lobe, the region ubiquitously atrophied in all symptomatic carriers. With each decade of age, an increasing percentage of presymptomatic carriers showed low mesial temporal volume, suggestive of early neurodegeneration.
• the journal of young scientists • berkeley scientific journal • the journal of young scientists • berkeley scientific jou / kŏn'těnt's / c o n t e n t s / bûrk'lē sī'en-tĭf'ĭk / B E R K E L E Y ... the Growing Threat of Desertification Julian Zhu interview with BsJ staff advisor leah carroll Kapil Gururangan, Sushrita Neogi, Prashant Bhat, Jared Rosen, Jingyan Wang interview with Professor ...doi:10.5070/bs3162015536 fatcat:tgpagqpzwffqrihxwoe4kli76e
The Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) and Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS) consortia are two closely connected studies, involving multiple North American centers that evaluate both sporadic and familial frontotemporal dementia (FTD) participants and study longitudinal changes. We screened the major dementia-associated genes in 302 sporadic and 390 familial (symptomatic or at-risk) participants enrolled indoi:10.1002/alz.12011 pmid:31914217 fatcat:hetcgxf56zeabpg4mkzl72nxce
more »... these studies. Among the sporadic patients, 16 (5.3%) carried chromosome 9 open reading frame 72 (C9orf72), microtubule-associated protein tau (MAPT), and progranulin (GRN) pathogenic variants, whereas in the familial series we identified 207 carriers from 146 families. Of interest, one patient was found to carry a homozygous C9orf72 expansion, while another carried both a C9orf72 expansion and a GRN pathogenic variant. We also identified likely pathogenic variants in the TAR DNA binding protein (TARDBP), presenilin 1 (PSEN1), and valosin containing protein (VCP) genes, and a subset of variants of unknown significance in other rare FTD genes. Our study reports the genetic characterization of a large FTD series and supports an unbiased sequencing screen, irrespective of clinical presentation or family history.
Y., 14649 Wong, Ka Sing, 14891 Wong, Maria, 14627 Wong, Mun-Chong, 14489 Wong, Philip S., 13516 Woo, Jean, 14891 Woo, Siew-Choo, 14489 Wood, David, 14727 Wood, Heather A., 14219 Wood, Jenifer L., 12972 ... ., 13914 Weiner, Bernard, 14197 Weiner, Rachel Leah, 15507 Weiner, Richard D., 14459 Weinryb, Robert . a Weinstein, H. ...
, Alan C.- N., 28216 Wong, Alfred, 30905 Wong, Angela, 28921 Wong, Gregory . 29400 Wong, M. - Wong, Rosanna Yin-mei, 29092 Wong, Sabrina, 2973: Wong, Stephen C. ... P., 29300 Wong, William C. ...
LEAH, J.D., HERDEGEN, T. & BRAvo, R. 1991. ... Tasuiro, T. & Komrya, Y. 1989. Stable and dynamic forms of cytoskeletal proteins in slow axonal transport. 7 Neurosci 9, 760-768. TasHtro, T. & Komiya, Y. 1991. ...
Public Health Reports
8 DO eee eee ee Se hecocesfucwese loscees accsniateese California: | | | Re eee ame 28, 806 3 ee | ae eee SCI Ry 12,923 |) ee Geer | See ’ | Seer | | ST ES aE 13, 536 TERRES erat Re Seay SR PRE nee 3 wong ... | } | | | | ER aE eee te 24,682 |........ |} 2]... 2 ee Se ee ee Bi ana Ph 6045 cen dasesnnteosees | 36, 397 21 | | |) Ser D tesco 1 1 Bloomington. .............-. | 28, 725 | as aa | Ser 5 Been pees leah ...
H.. 35986 Karsten, 34473 If, Pedr 3 Wolff, Marie, 36427 Wolfhagen e, 36644 35558 Wong. ( Yd Wong 365RO Wooden! ... E., 34557, 34571 y. Katherine, 35026 Wills, Wendy J., 34852 xlix Wilson, Ashley, 341 Wilson, J. T. ...
« Previous Showing results 1 — 15 out of 593 results